LEADER 01118nam0-22003251i-450-
001 990000148470403321
005 20161025171745.0
010   $a0-471-14899-7
035   $a000014847
035   $aFED01000014847
035   $a(Aleph)000014847FED01
035   $a000014847
100   $a20020821d--------km-y0itay50------ba
101 0 $aita
105   $ay-------001yy
200 1 $aDoing statistics with Excel for Windows (tm)$eversion 5.0$ean intoductory course supplement for explorations in data analysis$fMarilyn K. Pelosi , Theresa M. Sandifer , Jerzy J. Letkowski.
210   $aNew York$cJ. Wiley$dcopyr. 1996
215   $aXII, 360 p.$cill.$d25 cm + floppy disk
610 0 $aMicroelaboratori elettronici$aProgrammi Microsoft Excel per Windows
610 0 $aMicroelaboratori elettronici$aProgrammi di statistica
676   $a005.369
700  1$aPelosi,$bMarilyn K.
702  1$aLetkowski,$bJerzy J.
702  1$aStandifer,$bTheresa M.
801  0$aIT$bUNINA$gRICA$2UNIMARC
901   $aBK
912   $a990000148470403321
952   $a13 P 04 16$b10765$fFINBC
959   $aFINBC
997   $aUNINA

LEADER 03146nam  22007215  450 
001 9910298278503321
005 20200701073828.0
010   $a3-319-16522-4
024 7 $a10.1007/978-3-319-16522-6
035   $a(CKB)3710000000414302
035   $a(EBL)2096871
035   $a(SSID)ssj0001500629
035   $a(PQKBManifestationID)11927797
035   $a(PQKBTitleCode)TC0001500629
035   $a(PQKBWorkID)11521615
035   $a(PQKB)11122249
035   $a(DE-He213)978-3-319-16522-6
035   $a(MiAaPQ)EBC2096871
035   $a(PPN)186030509
035   $a(EXLCZ)993710000000414302
100   $a20150514d2015      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aCognitive Enhancement /$fedited by Kathleen M. Kantak, Joseph G. Wettstein
205   $a1st ed. 2015.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015.
215   $a1 online resource (466 p.)
225 1 $aHandbook of Experimental Pharmacology,$x0171-2004 ;$v228
300   $aDescription based upon print version of record.
311   $a3-319-16521-6 
320   $aIncludes bibliographical references at the end of each chapters and index.
327   $aPreface -- Part 1. Basic Approaches and Perspectives -- Part 2. Cognitive Domains for Pharmacological Intervention: Implications for Neuropsychiatric and Neurological Illnesses -- Part 3. Developmental Disorders, Emerging Technologies and Ethical Considerations.
330   $aThis book highlights the behavioral and neurobiological issues relevant for drug development, reviews evidence for an innovative approach for drug discovery and presents perspectives on multiple special topics ranging from therapeutic drug use in children, emerging technologies and non-pharmacological approaches to cognitive enhancement.
410  0$aHandbook of Experimental Pharmacology,$x0171-2004 ;$v228
606   $aPharmacology
606   $aNeurosciences
606   $aNeurology
606   $aPsychopharmacology
606   $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007
606   $aNeurosciences$3https://scigraph.springernature.com/ontologies/product-market-codes/B18006
606   $aNeurology$3https://scigraph.springernature.com/ontologies/product-market-codes/H36001
606   $aPsychopharmacology$3https://scigraph.springernature.com/ontologies/product-market-codes/H53010
615  0$aPharmacology.
615  0$aNeurosciences.
615  0$aNeurology.
615  0$aPsychopharmacology.
615 14$aPharmacology/Toxicology.
615 24$aNeurosciences.
615 24$aNeurology.
615 24$aPsychopharmacology.
676   $a616.89142
702   $aKantak$b Kathleen M$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aWettstein$b Joseph G$4edt$4http://id.loc.gov/vocabulary/relators/edt
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910298278503321
996   $aCognitive enhancement$91383062
997   $aUNINA